【摘 要】
：
Hypogonadotropic hypogonadism (HH) is a rare disease in which medical treatment has a high success rate to achieve fertility.This study aimed to analyze the efficacy of hormone replacement therapy and determine predictive factors for successful spermatoge
【机 构】
：
Haseki Training and Research Hospital, Department of Urology, Istanbul 34096, Turkey;Department of U
论文部分内容阅读
Hypogonadotropic hypogonadism (HH) is a rare disease in which medical treatment has a high success rate to achieve fertility.This study aimed to analyze the efficacy of hormone replacement therapy and determine predictive factors for successful spermatogenesis and spontaneous pregnancy in patients with idiopathic HH.A total of 112 patients with low testosterone (T),luteinizing hormone (LH) and follicle-stimulating hormone (FSH),and normal prolactin levels were diagnosed with HH and administered LH and FSH analogs as hormone replacement therapy.During treatment,96 (85.7％) patients had sperm present in ejaculate samples.Among these patients,72 were married and wanted a child.Of these 72 patients,48 (66.7％) of couples had pregnancies from natural conception.After initiation of treatment,the mean time for the appearance of sperm in semen was 9.48 months.There were no significant differences between baseline FSH,T,and LH levels;however,older age,larger testicular size,and low rate of undescended testes were favorable factors for successful spermatogenesis.Larger testicular size and older age were also the main predictive factors for natural conception.We found that patients with undescended testes had a younger age,smaller testes,and lower T levels compared with patients exhibiting descended testes.The rate of sperm found in the ejaculate was not significantly decreased in patients with undescended compared with descended testis (73.7％ vs 87.6％,P =0.261).The medical approach for males with HH and azoospermia provides a successful treatment modality in regard to successful spermatogenesis and achievement of pregnancy.
其他文献
To interact with the egg,the spermatozoon must undergo several biochemical and motility modifications in the female reproductive tract,collectively called capacitation.Only capacitated sperm can undergo acrosomal exocytosis,near or on the egg,a process th
Even in the era of novel targeted agents,switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC),especially in undeveloped countries.However,whether prior treatme
An increased amount of DNA fragmentation in the spermatozoa (SDF) is linked to male infertility.The Sperm Chromatin Structure Assay (SCSA) is widely used for analysis of SDF.However,the current software (SCSASof(R)) linked to this assay is licensed and of
Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCa) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to in
B lymphoma Moloney murine leukemia virus insertion region 1 (BMI1),a core member of polycomb repressive complex 1 (PRC1),has been intensely investigated in the field of cancer epigenetics for decades.Widely known as a critical regulator in cellular physio
Emerging evidence indicates that aldosterone and mineralocorticoid receptors (MRs) are associated with the pathogenesis of erectile dysfunction. However, the molecular mechanisms remain largely unknown. In this study, freshly isolated penile corpus cavern
The impact of sexual dysfunction (SD) is distressing to many male patients with pituitary adenomas which affect both physical and psychological health. The research explored to identify risk factors affecting sexual function and the prognosis of male pati
Several authors have commented on the anatomical changes following radical prostatectomy (RP) for prostate cancer and their characteristic radiological appearances.1,2 Most of these relate to periurethral fibrosis and its clinical significance in patients
Dear Editor,rnIntensive treatments such as primary androgen deprivation therapy (pADT) plus docetaxel or abiraterone acetate are reportedly beneficial in metastatic prostate cancer (mPCa) patients with high-volume disease or high-risk features,respectivel